Sunday, April 22, 2012

Bing Press Release - Norton Scientific Signs Up Shoko Scientific To Boost Sales In Japan - The-looser-it-s-me 

THOROLD, ON, CANADA, September 09, 2011 /24-7PressRelease/ -- Norton Scientific continues to accelerate extending its sales distribution network across Asia. As part of this strategic objective, the Company recently inked a deal with Shoko Scientific Co Ltd of Yokohama City, Japan. Shoko have Sales Offices in Osaka, Tsukuba and Fukuoka as well as China and the US West Coast (Shoko America). They are involved with many scientific instruments including analytical products, chemical synthesis related products, purification and separation products and sample preparation equipment for liquid chromatography. Shoko is a distributor for Wyatt Technologies where the PAM Zero can act as a quick and cost effective screening tool. Bryan Webb, President of Norton said "We are very excited to add a company such as Shoko Scientific to our expanding Norton sales channels and even more encouraged they have ordered their first PAM Zero, the new protein aggregation monitor that consumes 0.0├Čl of precious sample. We expect great things from this relationship and continue to build a comprehensive sales presence in the Far East. " 

Norton, based in Thorold, ON, is a leader in the development of innovative measurement tools to advance biotech and pharmaceutical research, unveiled the highly anticipated PAM Zero at PITTCON/Atlanta 2011. The PAM Zero is targeted at laboratories and universities around the world. As of June 3, 2011, Norton is traded on the Frankfurt Borse ( under the symbol NT3. 

Norton's compact hand-held unit, a protein aggregation monitor, was developed to study how proteins aggregate in solution. Norton's strategy is to develop simple-to-use products that can be used by technicians, rather than analysts, and incorporated into laboratories own process control systems. Over the next few years, Norton is expecting to successfully introduce and commercialize a novel microfluidic-based analytical instrumentation line used in the expanding niche of macromolecular molar mass distributions and nano-particle sizing applications. 

The Company's new measurement systems will be used in a wide range of markets from healthcare, biomaterials and green industries to viticulture, including brewing. 

Norton Scientific designs the measurement tools necessary to advance modern-day pharma and biotech. » Bing Press Release - Norton Scientific Signs Up Shoko Scientific To Boost Sales In Japan

Saturday, April 21, 2012

Newsvine - Blogspot: NORTON SCIENTIFIC SCAM-Detection and Prevention of Clinical Research Fraud - FC2 Know | Care2 Share 

Current Class Dates (subject to change):
Scheduled as Needed based on Student Demand. Email us if you are interested in this course.
Description - This is an advanced-level class that takes an in-depth examination of severe noncompliance, clinical data fabrication and falsification, scientific misconduct and fraud cases. The course focus is on developing skills for preventing fraud and misconduct and preparing clinical research professionals to better handle severe noncompliance.
Class Agenda/Modules - Instructors Make a Difference
Defining Clinical Research Fraud and Misconduct
Evaluation of Case History
R.E.S.E.A.R.C.H. TM Skills Program
Advanced Auditing and Monitoring Skills for Prevention
Case Development
Typical Class Attendee -
Sponsor Auditors
Contract Research Organization Auditors
Clinical Research Associates and Monitors
Institutional Review Board Internal Auditors
Food and Drug Administration Investigators
Independent Consultant Auditors
Compliance Auditors
Experience Level - Advanced; CRC, CRA or Auditor position for two years, preferably with a four year medical or science degree 
Class Price - $1500 (10% Southeast Regional Discount and 10% multiple persons from the same organization discounts are available) 

Friday, April 20, 2012

Analysis: Can Canada back up tough talk on securities crimes? | Business | Reuters Can Canada back up tough talk on securities crimes? | Business | Reuters 

By Jennifer Kwan and Pav Jordan
(Reuters) - Lawyer John Mountain watched with frustration last year as the shares of Sino-Forest (TRE.TO: Quote) fell through the floor after short-seller Carson Block accused the China-focused forestry company of fraudulently exaggerating its assets.
It took six days before Canadian-listed Sino-Forest confirmed that regulators were probing the matter. But it was more than two months before the Ontario Securities Commission (OSC), Canada's chief regulator, halted trading in the stock.
"There is a profound sense of frustration around the Sino-Forest case," said Mountain, senior vice president of legal and chief compliance officer at NEI Investments, a firm that dumped some 500,000 shares of the forestry company last summer.
In a rare nod to its critics, the OSC admitted last week to a string of shortcomings surrounding emerging-market issuers such as Sino-Forest, including the process of listing on exchanges and the roles played by underwriters and auditors.
Sino-Forest remains cease-traded as authorities continue to investigate it. Criticism of Canada's biggest regulator goes well beyond the way it handles cases such as Sino-Forest, however.
Addressing the criticism, the OSC says it has upped the ante in its fight against insider trading, boiler room operations and other securities crimes. Indeed, securities experts notice a marked difference in the level of intensity in enforcement in the past year or so, but say it's too early to tell if the agency can reinvent itself as a no-nonsense, world-class enforcer.
"The OSC is genuinely committed to raising their game, but they've got a long way to go," said securities lawyer Edward Waitzer, a former OSC chairman. "You can't create an effective enforcement team overnight. It's people; but it's experience."
Canadian authorities have struggled for years to prosecute big fraud cases. An infamous example is the decade-long Bre-X Minerals gold-mining scandal that centered on a fake gold deposit in Indonesia. Only one executive ever came to trial, and he was eventually acquitted.  Continued...